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Conclusion: La mortalité associée aux méningites bactériennes aigues demeure toujours élevée au Burkina Faso malgré la disparition totale du NmA depuis 2012 suite à l'introduction du vaccin conjugué A (MenAfriVac). Cependant l'émergence de NmX, la réémergence de NmW, et la persistance de la forte prévalence du Streptococcus pneumoniae constituent une
INTRODUCTION
Acute bacterial meningitis is a major public health problem in the south-Sahara African area and particularly in Burkina Faso (1). This disease is a serious disease that can cause death within hours or may leave significant neurological sequelae (1, 2). Meningococcus is responsible for major epidemics, usually every 5-10 years, causing many cases of deaths in the population (3 
MATERIALS AND METHODS

Study sites
The study was conducted in thirteen (13) health regions of Burkina Faso: the Boucle of Mouhoun, the Cascades, the Centre, the Centre-East, the Centre-North, the Centre-West, the Centre-South, the East, the Hauts-Bassins, the North, the Plateau Central, the Sahel and the South-West regions. The country has a National Reference Laboratory for meningitis (NRL) that is the Charles De Gaulle University teaching Hospital laboratory of Bacteriology-Virology and four (4) national laboratories located in the University teaching Hospital of Yalgado Ouedraogo, the University teaching of Hospital Souro Sanou, the Centre Muraz and the National Laboratory of Public Health. Each region, through its health districts is affiliated to a laboratory for CSF analysis and isolation of germs.
Type and period of the study The study was descriptive retrospective and was performed for analytical purposes. It covered ten years period, from January 2005 to December 2014.
Sampling and sample
The sampling method was exhaustive: the sample comprised of all cerebrospinal meningitis cases registered in the Ministry of Health database (national epidemiological surveillance system) during the study period.
Cases of cerebrospinal meningitis of all health regions were selected and classified as suspected and confirmed cases, in accordance with the WHO definition of acute bacterial meningitis.
Data collection
Data was collected for analysis purpose on an especially designed form for each case. Clinical records, case filings forms, sampling bulletins and CSF analysis results were the primary tools for data collection.
Results
From 2005-2014, Burkina Faso recorded a lethality rate of 10.37 %. 5775 (6.55 %) of these suspected cases have been laboratory confirmed. 
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FIGURE 2: DYNAMICS OF GERMS DISTRIBUTION ACCORDING TO THE HEALTH REGION
Among the suspected cases, the bacterial meningitis confirmed for 5775 patients, One limitation of our study is related to the low rate of laboratory ses: less than 7% of cases have been Several studies reveal the insufficient use of the laboratory in meningitis surveillance in the meningitidis belt countries (6, 7). This situation could be explained by the integrated system set up in Burkina Faso before the introduction of the serogroup A anti meningococcal conjugate vaccine, the MenAfriVac vaccination with MenAfriVac, the country adopted a surveillance system in which cted case is In addition, since 2010 the use of realtime PCR increased the laboratories capacities for N. In general, we found that the lethality due to NmX and NmW is equivalent or even higher than that caused by NmA; this finding has been revealed by other authors (21, 24, 25) .
Besides the Neisseria meningitidis, the study has shown the significant proportion of Streptococcus pneumoniae (41.09%) in the occurrence of cerebrospinal meningitis during the past decade in Burkina Faso. This germ, well-known for its high lethality (26, 27) has been observed since 2009; however it had a net increase after vaccination with MenAfriVac. In 2011, it represented almost 72% (798/1114) of the isolates; during the same year we have recorded 3878 cases of meningitis with 588 deaths, that is to say a lethality rate of 15.16%. Since 2011, there has been noticed a decrease of cases but the number of cases remained high from 2012 to 2014: it was respectively 502 cases in 2012, 351 in 2013 and 507 cases in 2014.
In addition to the three (03) most affected health regions by the NmW, other regions such as the Centre-West, North and Plateau Central regions had shown a high number of cases Spn.
CONCLUSION
Cerebrospinal meningitis continues to cause high mortality in Burkina Faso population although no NmA case has been isolated since 2011, reflecting effective action of MenAfriVac vaccination against this serogroup. However the emergence of NmX serogroup in 2010 and re-emergence of NmW serogroup since 2012 remain a major concern in the fight against meningococcal meningitis. In addition, the study has identified Streptococcus pneumoniae as a significant cause of high mortality of cerebrospinal meningitis in Burkina Faso. If a vaccine against NmX has not yet been developed , a conjugate vaccine against pneumococcus, which takes into account most of Spn serotypes encountered in Burkina Faso has been introduced in the childhood immunization program since 2013,. Similarly, polysaccharide vaccine against the NmW serogroup exists but has a limited access for developing countries populations such as Burkina Faso. Given this change in the epidemiological situation that is heterogeneous and dynamic geographically and through years, highlighting the emergence of NmX, the reemergence of NmW, and the persistence of high prevalence of Streptococcus pneumoniae, it appears imperative to reinforce preventive and case management strategies.
Thus, in addition to the strengthening of the surveillance which is essential to monitor these changes and remain able to detect epidemics caused by every serogroup of Nm; it is imperative to develop a trivalent conjugated vaccine covering NmA, NmX, and NmW serogroups and to make it available to the population. Such vaccine would be particularly useful for the prevention of meningococcal disease in the African meningitis belt and could protect against more than 90% of invasive cases of meningococcal meningitis. The major challenge after the vaccine development would be for the country to integrate it systematically into the national immunization program. 
